Cellosaurus logo
expasy logo
Due to maintenance work, this service will be unavailable Tuesday 16 between 06:00 and 06:30 - CEST. Apologies for the inconvenience.

Cellosaurus Hs 633.T (CVCL_0832)

[Text version]
Cell line name Hs 633.T
Synonyms Hs-633-T; Hs 633T; HS 633T; HS-633T; Hs633T; MBA/8387; MB 8387; 8387; Line 8387; HS 8387
Accession CVCL_0832
Secondary accession CVCL_0129
Resource Identification Initiative To cite this cell line use: Hs 633.T (RRID:CVCL_0832)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
Microsatellite instability: Stable (MSS) (PubMed=31068700; Sanger).
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Sequence variations
  • Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Pro (c.436G>C); ClinVar=VCV000375963; Zygosity=Heterozygous (Cosmic-CLP=1240149; DepMap=ACH-002246).
  • Mutation; HGNC; 11998; TP53; Simple; p.Glu285Argfs*60 (c.852delA); Zygosity=Heterozygous (Cosmic-CLP=1240149; DepMap=ACH-002246).
Disease Fibrosarcoma (NCIt: C3043)
Fibrosarcoma (ORDO: Orphanet_2030)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_G137 (HuT-11)CVCL_G138 (HuT-12)CVCL_G139 (HuT-13)
CVCL_G140 (HuT-14)
Sex of cell Female
Age at sampling 25Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP=1240149

Markers:
AmelogeninX
CSF1PO11,12
D5S81812
D7S8208,11
D13S31711,12
D16S53911
TH016,9
TPOX11
vWA15,20

Run an STR similarity search on this cell line
Publications

PubMed=5431618; DOI=10.1016/0014-4827(70)90250-8
Aaronson S.A., Todaro G.J., Freeman A.E.
Human sarcoma cells in culture. Identification by colony-forming ability on monolayers of normal cells.
Exp. Cell Res. 61:1-5(1970)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=375235; DOI=10.1073/pnas.76.3.1288
Sherwin S.A., Sliski A.H., Todaro G.J.
Human melanoma cells have both nerve growth factor and nerve growth factor-specific receptors on their cell surfaces.
Proc. Natl. Acad. Sci. U.S.A. 76:1288-1292(1979)

PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=6954533; DOI=10.1073/pnas.79.7.2194
Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A., Aaronson S.A., Wong-Staal F.
Differential expression of the amv gene in human hematopoietic cells.
Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982)

PubMed=6500159; DOI=10.1159/000163283
Gershwin M.E., Lentz D., Owens R.B.
Relationship between karyotype of tissue culture lines and tumorigenicity in nude mice.
Exp. Cell Biol. 52:361-370(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=2902939; DOI=10.1093/carcin/9.11.2073
McCormick J.J., Yang D.-J., Maher V.M., Farber R.A., Neuman W., Peterson W.D. Jr., Pollack M.S.
The HuT series of 'carcinogen-transformed' human fibroblast cell lines are derived from the human fibrosarcoma cell line 8387.
Carcinogenesis 9:2073-2079(1988)

PubMed=1385192; DOI=10.1016/0531-5565(92)90007-m
Fleming T.P., Matsui T., Aaronson S.A.
Platelet-derived growth factor (PDGF) receptor activation in cell transformation and human malignancy.
Exp. Gerontol. 27:523-532(1992)

PubMed=8188761; DOI=10.1002/jcp.1041590307
Cuadrado A., Issing W., Fleming T.P., Molloy C.J.
Uneven distribution of protein kinase C-alpha and -beta isozymes in human sarcomas and carcinomas.
J. Cell. Physiol. 159:434-440(1994)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) ATCC; CRL-7395 - Discontinued
ECACC; 89050201
Cell line databases/resources CLO; CLO_0004034
MCCL; MCC:0000021
CLDB; cl1718
cancercelllines; CVCL_0832
Cell_Model_Passport; SIDM00667
Cosmic-CLP; 1240149
DepMap; ACH-002246
LINCS_LDP; LCL-1436
Chemistry resources GDSC; 1240149
PharmacoDB; Hs633T_615_2019
Encyclopedic resources Wikidata; Q54895847
Gene expression databases ArrayExpress; E-MTAB-3610
GEO; GSM827368
GEO; GSM1669896
Polymorphism and mutation databases Cosmic; 1995445
Cosmic; 2009543
Progenetix; CVCL_0832
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update02-May-2024
Version number30